18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0Primary· 0 to 30 days
Data will be collected and entered into Case Report Form in local REDCap sever to include MedDRA Code, Grade and all other data required by NIH per Memorandum, "Guidance for Collection of Adverse Events Related to COVID-19 Infection" dated on 25 March 2020. All data will be reported per this memorandum and in accordance with all applicable Institutional Review Board and FDA requirements.
Group
Value
95% CI
Low Dose N-Acetyl Cysteine Alone
0
Rate of HospitalizationSecondary· 0 to 30 days
Number of participants hospitalized
Group
Value
95% CI
Low Dose N-Acetyl Cysteine Alone
0
Time to Symptom ResolutionSecondary· 0 to 30 days
Days to resolution of symptoms of infection.
Group
Value
95% CI
Low Dose N-Acetyl Cysteine Alone
6
6 – 6
Sponsor's own description
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta
· Phase 1
· not yet recruiting
NCT07101445 — Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injecti
· Phase 4
· recruiting
NCT06743243 — Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia
· Phase 4
· enrolling by invitation
NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm
· Phase 1
· completed
NCT06819670 — A Study to Prevent Infantile Spasms Relapse
· Phase 2
· recruiting
Other recruiting trials for Covid19
Currently open trials in the same condition.
NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
· EARLY_PHASE1
· active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
· NA
· recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
· NA
· active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry
· recruiting
NCT04806061 — Urine Alkalinisation in COVID-19
· NA
· active not recruiting
Other Prisma Health-Upstate trials
Trials by the same sponsor.
NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
· NA
· not yet recruiting
NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure
· Phase 4
· withdrawn
NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent
· NA
· enrolling by invitation
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
Last refreshed: 18 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04545008.